UZCHS-CTU, in collaboration with UCSF, has been awarded continued Clinical Trials Unit (CTU) funding from the US National Institute of Allergy and Infectious Diseases (NIAID) to continue conducting high quality HIV treatment and prevention studies through 2021. The CTU will continue to operate seven clinical research sites, which operate under four NIAID sponsored research networks: ACTG, HPTN, IMPAACT, and MTN. Research priority areas will include adult HIV therapeutic strategies, including HIV cure and both infectious and non-infectious co-morbidities; prevention of mother to child transmission and HIV-associated infections in pediatric and maternal populations; integrated HIV prevention strategies; and microbicides for prevention in women.
Over the next seven years, UZCHS-CTU looks forward to increased research with novel therapies such as HIV vaccines and therapies to address antibacterial resistance through future NIAID research networks. We are proud to be one of 37 selected NIAID-sponsored CTUs worldwide.
UZCHS-CTU is located in Harare, Zimbabwe and aims to serve as a Center of Excellence in the prevention and control of HIV/AIDS and contribute to global health policies and improved standards of care. The CTU will continue to be led by UCSF CTU PI, Z.M. Chirenje, MD, FRCOG.